Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Japan Is Creating New Opportunities in the Field of Regenerative Medicine - SPONSOR CONTENT FROM THE GOVERNMENT OF JAPAN
As biotech companies race toward the opportunities in Japan, no life sciences sector has received more attention, government support, and regulatory reform than the important field of regenerative medicine. Regeneratives are pharmaceutical cell therapy products that replace or restore cells and tissues lost to disease or aging. Some regenerative medicines stimulate our bodies to regrow or repair, so the field can include the use of stem cells for tissue engineering. Japan’s rapidly aging population creates a perfect test kitchen for such regeneratives, especially as the aging trend expands to Europe and North America. Meanwhile, regenerative medicine is at the forefront of scores of research partnerships between private biotech companies and Japanese universities. “The Japanese want to be the regenerative medicine center of the world,” said Colin Lee Novick, managing director of the CJ Partners biotech consulting firm in Tokyo. “To be able to do that, they need to entice companies to come to Japan, and they need to entice their own pharmaceutical companies to license in and obtain the best.” The “regen” boom in Japan is based on a series of reforms and new laws for pharmaceuticals, but especially the landmark Pharmaceuticals and Medical Devices Act (PMD Act) and the Act on the Safety of Regenerative Medicine. The result is the ability to offer conditional marketing approval for a regen so it can move more quickly to commercialization – an approval process widely seen as the fastest in the world. Regens also benefit from what is known as the Sakigake Package of policy changes, which speed up the introduction of innovative medical products. The package focuses on everything from basic research to clinical research/trials, approval reviews, safety measures, insurance coverage, improvement of infrastructure and the environment for corporate activities, and global expansion. It includes a designation system that promotes R&D in Japan aimed at early practical application for innovative pharmaceutical products, medical devices, and regenerative medicines. It also includes a scheme for rapid authorization of unapproved drugs, which speeds the practical application of unapproved/off-label use of drugs for serious and life-threatening diseases. But the benefits don’t stop there, Novick points out. In addition to the conditional approval and Sakigake benefits, Japanese regens arrive in one of the world’s largest markets for pharmaceuticals. The result since 2014 has been a flood of partnerships, research studies, and licensing deals. Gene therapy is also a part of this trend. Agilis Biotherapeutics, a U.S. company, is partnered with Gene Therapy Research Institution of Japan to develop and obtain approval for medicines to treat Parkinson’s disease and another nerve disease. “R&D requires extremely high skills, but manufacturing requires even higher skills. There are very few places that can provide high-quality manufacturing capabilities in the U.S. and also in the world. After a thorough valuation, they came to believe the Japanese Gene Therapy Research Institution had the best capabilities (talent and skills),” said President Katsuhito Asai of Agilis GTRI Japan, a joint venture between Agilis and the Japanese Gene Therapy Research Institution. Foreign companies that have decided to conduct R&D in Japan for innovative medical products are entitled to a research grant from METI to help with their capital investment. In addition, local governments provide their own grants. Agilis GTRI Japan is located in a public-private research park in Kanagawa Prefecture, which has adopted the National Strategic Special Zone concept to cut regulation and offer other benefits for innovation companies. Among the larger partnerships are some iconic Japanese companies. Nikon continues to move into health care by partnering with Lonza of Switzerland – the world’s leading developer of regenerative medicine cells – to build a cell and gene therapy manufacturing plant. Hitachi has partnered with Caladrius Biosciences of the U.S., and Asahi Glass Co. is working with Regeneus of Australia. That these classic Japanese companies known for products in other fields are moving into life sciences underscores the lure of both regens and Japan’s lucrative home markets. Other partnerships or licensing deals involve Athersys of the U.S. and Healios of Tokyo, to develop and produce the MultiStem therapy for stroke victims; Celixir of the U.K., working with Daiichi Sankyo on the Heartcel heart failure medicine; the Belgian firm TiGenix partnering with Takeda Pharmaceuticals on a Crohn’s disease treatment; and Kolon Life Science of South Korea collaborating on the Invossa arthritis drug with Mitsubishi Tanabe Pharmaceutical Co. The mutual benefits of such partnerships were demonstrated when Takeda recently announced it was buying TiGenix. Among the companies directly crediting the conditional approval process in Japan for its interest is Israel’s Pluristem, which is partnering with Sosei CVC to develop placenta-derived cells to speed healing in patients with critical limb ischemia, or CLI. “The development of our CLI program through the accelerated regulatory pathway could allow a more rapid entrance into the sizeable Japanese market, as has been our strategy,” said Zami Aberman, Pluristem’s chairman and CEO. In regeneratives and the broader field of pharmaceuticals, a plethora of non-Japanese companies have formed research collaborations with Japanese universities, which have in recent years moved strongly into commercialization and outside relationships. From the U.S., Merck and Pfizer are working with the University of Tokyo, and the U.K’s AstraZeneca conducts collaborative research with Osaka University and National Cancer Center Japan. Pluristem works with Fukushima Medical University. Pointing out the many deals, collaborations, and new regen opportunities, the consultant Novick advises non-Japanese companies to “definitely jump in. … It’s a nascent and rapid-growth market. Because the cement is still drying on the rules and regulations and guidelines, if you want to be one of the parties that is going to be able to set the tone in this market, you must enter now.” Find more at Japan.go.jp/abenomics.
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.
Seattle Genetics (SGEN) beats estimates on both counts on the back of strong Adcetris sales.
Amgen (AMGN) gains consent from the Committee for Medicinal Products for Human Use to add overall survival data from a phase III study on the label of its cancer drug, Kyprolis.
Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.
Японская фармацевтическая компания Takeda Pharmaceutical Company Limited подписала соглашение о покупке прав на ряд безрецептурных препаратов и биодобавок у американской компании Unipharm, говорится в сообщении Takeda.
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.
Seattle Genetics (SGEN) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Seattle Genetics (SGEN) reported narrower-than-estimated loss in the third quarter. Moreover, including a warrant exercise it turned profitable. The shares were up in response.
Seattle Genetics (SGEN) incurred narrower-than-expected loss in Q2 and provided an encouraging guidance for Adcetris.